Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in treating HER-2 positive advanced breast cancer in Taiwan

Breast J. 2020 Oct;26(10):2099-2102. doi: 10.1111/tbj.14053. Epub 2020 Sep 17.
No abstract available

Keywords: T-DM1; cost-effectiveness analysis; metastatic breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ado-Trastuzumab Emtansine
  • Antineoplastic Agents* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Receptor, ErbB-2
  • Taiwan
  • Trastuzumab / therapeutic use

Substances

  • Antineoplastic Agents
  • Receptor, ErbB-2
  • Trastuzumab
  • Ado-Trastuzumab Emtansine